Clinical Trials

As part of the CIRM Alpha Stem Cell Clinics Network, City of Hope Alpha Clinic is pursuing its goal to accelerate the development and delivery of stem cell therapies to patients through high quality clinical trials.

Ongoing trials at City of Hope Alpha Clinic include:

A Phase I Study of Cytosine Deaminase-Expressing Neural Stem Cells in Combination with Oral 5-Fluorocytosine and Leucovorin for the Treatment of Recurrent High Grade Gliomas (COH Protocol #13401)

Status of enrollment: Open to accrual

Disease Indication:

  • Adult Anaplastic Astrocytoma

  • Adult Anaplastic Oligodendroglioma

  • Adult Giant Cell Glioblastoma

  • Adult Glioblastoma

  • Adult Gliosarcoma

  • Recurrent Adult Brain Tumor

  • Anaplastic Oligoastrocytoma

Trial Contact:
Alexandra Ching, NP
626-471-9393
[email protected]

Study details on clinicaltrials.gov

 

Safety and Feasibility of Gene Transfer After Frontline Chemotherapy for Non-Hodgkin Lymphoma in AIDS Patients Using Peripheral Blood Stem/ Progenitor cells Treated with a Lentivirus Vector-Encoding Multiple Anti-HIV RNAs (COH Protocal #13282)

Status of enrollment: Open to accrual

Disease Indication:

  • AIDS-related Diffuse Large Cell Lymphoma

  • AIDS-related Diffuse Mixed Cell Lymphoma

  • AIDS-related Diffuse Small Cleaved Cell Lymphoma

  • AIDS-related Immunoblastic Large Cell Lymphoma

  • AIDS-related Lymphoblastic Lymphoma

  • AIDS-related Small Noncleaved Cell Lymphoma

  • HIV Infection

Trial Contact:
Amrita Krishnan, M.D.
626-218-2405
[email protected]

Study details on clinicaltrials.gov

 

A Pilot Study to Evaluate the Feasibility, Safety and Engraftment of Zinc-Finger Nucleases (ZFN) CCR5 Modified CD34+ Hematopoietic Stem/Progenitor Cells (SB-728MR-HSPC) in HIV-1 (R5) Infected Patients (COH Protocol #14017)

Status of enrollment: Open to accrual

Disease Indication:

  • HIV-1 (R5) Infection w/ suboptimal CD4 levels while on cART

Trial Contact:
Rodica Stan, Ph.D.
626-218-8330
[email protected]

Study details on clinicaltrials.gov

 

Phase I Study of Cellular Immunotherapy Using Central Memory Enriched T-Cells Lentivirally Transduced to Express an IL13Rα2-Specific, Hinged-Optimized, 41BB-Costimulatory Chimeric Receptor and a Truncated CD19 for Patients with Recurrent/Refractory Malignant Glioma (COH Protocol #13384)

Status of enrollment: Open to accrual

Disease Indication:

  • Malignant Glioma

    • Refractory Brain Neoplasm

    • Recurrent Brain Neoplasm

Trial Contact:
Fetemah Bidmeshki
626-218-9393
[email protected]

Study details on clinicaltrials.gov

 

Phase I Study of Cellular Immunotherapy Using T Cells Lentivirally Transduced to Express a CD123-Specific, Hinge-Optimized, CD28-Costimulatory Chimeric Antigen Receptor and a Truncated EGFR for Patients With Relapsed or Refractory CD123+ Acute Myeloid Leukemia (COH Protocol #13272)

Status of enrollment: Open to accrual

Disease Indication:

  • Relapsed Acute Myeloid Leukemia

  • Refractory Acute Myeloid Leukemia

Trial Contact:
Lihua Budde, M.D., Ph.D.
800-826-4673
[email protected]

Study details on clinicaltrials.gov

 

A Phase I/IIa, Open Label Clinical Trial Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs Specific for NY-ESO-1 in Patients With Recurrent or Treatment Refractory Ovarian Cancer (COH Protocol #12291)

Status of enrollment: Open to accrual

Disease Indication:

  • Recurrent Ovarian Cancer

  • Refractory Ovarian Cancer

Trial Contact:
Mihaela Cristea, M.D.
626-218-2405
[email protected]

Study details on clinicaltrials.gov

 

A Pilot Study of Genetically Engineered NY-ESO-1 Specific (c259) T cells in HLA-A2+ Patients with Synovial Sarcoma (COH Protocol #15242)

Status of enrollment: Open to accrual

Disease Indication:

  • Synovial Sarcoma

Trial Contact:
Warren Chow, M.D.
626-218-9200
[email protected]

Study details on clinicaltrials.gov

 

A Phase I/ II Dose Escalation Open Label Clinical Trial Evaluating the Safety and Efficacy of MAGE A10ᶜ⁷⁹⁶T in Subjects With Stage IIIb or Stage IV Non-Small Cell Lung Cancer (COH Protocol #15303)

Status of enrollment: Open to accrual

Disease Indication:

  • Advanced Non-Small Cell Lung Cancer (Stage IIIb or IV)

  • Recurrent Non-Small Cell Lung Cancer

Trial Contact:
Karen Reckamp, M.D.
626-218-9200
[email protected]

Study details on clinicaltrials.gov

 

A Phase I/II Open Label Clinical Trial Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs Specific for NY-ESO-1 in Subjects With Stage IIIb or Stage IV Non-Small Cell Lung Cancer (COH Protocol #15275)

Status of enrollment: Open to accrual

Disease Indication:

  • Advanced Non-Small Cell Lung Cancer (Stage IIIb or IV)

  • Recurrent Non-Small Cell Lung Cancer

Trial Contact:
Karen Reckamp, M.D.
626-218-9200
[email protected]

Study details on clinicaltrials.gov

 

A Screening Protocol to Determine Tumor Antigen Expression and HLA Sub-Type for Eligibility Determination for Clinical Trials Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs in Subjects With Non-Small Cell Lung Cancer (COH Protocol #15346)

Status of enrollment: Open to accrual

Disease Indication:

  • Advanced Non-Small Cell Lung Cancer (Stage IIIb or IV)

  • Recurrent Non-Small Cell Lung Cancer

Trial Contact:
Karen Reckamp, M.D.
626-218-9200
[email protected]

Study details on clinicaltrials.gov

 

Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (NHL) (COH Protocol #15209)

Status of enrollment: Open to accrual

Disease Indication:

  •  B-cell Non-Hodgkin Lymphoma (NHL)

Trial Contact:
Tanya Siddiqi, M.D.
626-218-2405
[email protected]

 

A Phase I, Open-Label, Ascending Dose Study to Assess the Safety and Tolerability of AAV2/6 Factor IX Gene Therapy Via Zinc Finger Nuclease (ZFN) Mediated Targeted Integration of SB-FIX in Adult Subjects With Severe Hemophilia B (COH Protocol #1542

Status of enrollment: Open to accrual

Disease indication:
  • Hemophilia B
Trial Contact:
Nadia P Ewing, M.D.
626-256-4673, ext. 88858
[email protected]

 

Carboxylesterase-Expressing Allogeneic Neural Stem Cells and Irinotecan Hydrochloride in Treating Patients With Recurrent High-Grade Gliomas (COH Protocol #14108)

Status of enrollment: Open to accrual

Disease indication:

  • Adult Anaplastic Astrocytoma

  • Adult Anaplastic Oligoastrocytoma

  • Adult Anaplastic Oligodendroglioma

  • Adult Glioblastoma

  • Adult Gliosarcoma

  • Recurrent Adult Brain Tumor

  • Glioma

Trial Contact:
Jana Portnow, M.D.
626-218-9200
[email protected]

Study details at clinicaltrials.gov


A Phase 1-2 Multi-Center Study Evaluating KTE-C19 in Subjects With Refractory Aggressive Non-Hodgkin Lymphoma (ZUMA-1) (COH Protocol #14240)

Status of enrollment: Open to accrual

Disease indication:

  • Refractory Diffuse Large B Cell Lymphoma

  • Refractory Primary Mediastinal B Cell Lymphoma

  • Refractory Transformed Follicular Lymphoma

  • Relapsed/Refractory Transplant Ineligible Diffuse Large B Cell Lymphoma

  • Relapsed/Refractory Transplant Ineligible Primary Mediastinal B Cell Lymphoma

  • Relapsed/Refractory Transplant Ineligible Transformed Follicular Lymphoma

Trial Contact:
Hormoz Mirshkarlo
[email protected]

Study details at clinicaltrials.gov


A Phase 2 Multicenter Study Evaluating Subjects With Relapsed/Refractory Mantle Cell Lymphoma (ZUMA-2) (COH Protocol #15166)

Status of enrollment: Open to accrual

Disease indication:

  • Relapsed/Refractory Mantle Cell Lymphoma

Trial Contact:
Hormoz Mirshkarlo     
[email protected]

Study details on clinicaltrials.gov


A Study Evaluating KTE-C19 in Combination With Atezolizumab in Subjects With Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (ZUMA-6) (COH Protocol #16279)

Status of enrollment: Open to accrual

Disease indication:

  • Refractory Diffuse Large B Cell Lymphoma

Trial Contact:
Hormoz Mirshkarlo     
[email protected]

Study details on clinicaltrials.gov

 

Multicentre, Randomized, Open-Label, Phase III Clinical Trial for Advanced Nasopharyngeal Carcinoma Patients (COH Protocol #16367)

Status of enrollment: Open to accrual

Disease indication:

  • Nasopharyngeal Cancer

Trial Contact:
Erminia Massarelli M.D, Ph.D.
626-218-9200

Study details at clinicaltrials.gov

 

NY-ESO-1C259T Alone and in Combination With Pembrolizumab for Multiple Myeloma (COH Protocol #17171)

Status of enrollment: Open to accrual

Disease indication:

  • HLA-A2+ SUBJECTS WITH NY-ESO-1 AND/OR LAGE-1A POSITIVE

  • RELAPSED AND REFRACT ORY MULTIPLE MYELOMA

Trial Contact:
Hormoz Babaei Mirshkarlo
626-218-8074
[email protected]

Study details at clinicaltrials.gov

 

Dose-Ranging Study of Recombinant AAV2/6 Human Factor 8 Gene Therapy SB-525 in Subjects with Severe Hemophilia A (COH Protocol #17068)

Status of enrollment: Open to accrual

Disease indication:

  • Hemophilia A

Trial Contact:  
Janice Kim, CCRP    
626-218-4350    
[email protected]  

Study details at clinicaltrials.gov